Lupin launches Favipiravir at Rs 49 to treat mild to moderate COVID-19 disease
Lupin launches Favipiravir at Rs 49 to treat mild to moderate COVID-19 disease

Lupin launches Favipiravir at Rs 49 to treat mild to moderate COVID-19 disease

Pratik Shastri Article rating: 3.8

The newly-launched drug, which was the need of the hour, would be available in the form of a strip of ten tablets, marketed under the brand name of Covihalt. It will be used to treat patients having a mild to moderate COVID-19 disease.

Zydus Cadila COVID-19 vaccine passes phase 1 human trials
Zydus Cadila COVID-19 vaccine passes phase 1 human trials

Zydus Cadila COVID-19 vaccine passes phase 1 human trials

DSIJ Intelligence Article rating: 4.7

Global pharmaceutical major, Zydus Cadila announced on Wednesday that its plasmid DNA vaccine to prevent COVID-19, namely ZyCoV-D, was found to be well-tolerated and safe in phase 1 clinical trial.

Lupin gets US health regulator nod for Empagliflozin tablets
Lupin gets US health regulator nod for Empagliflozin tablets

Lupin gets US health regulator nod for Empagliflozin tablets

DSIJ Intelligence Article rating: 4.3

Pharma major, Lupin Limited had announced on Tuesday that it has received regulatory approval from United States Food and Drug Administration (USFDA) for its Empagliflozin tablets, 10 mg and 25 mg to market a generic version of Jardiance tablets, 10 mg, and 25 mg, of Boehringer Ingelheim Pharmaceuticals.

Too many funds spoil the fun
Too many funds spoil the fun

Too many funds spoil the fun

DSIJ Intelligence Article rating: 4.0

Most people believe in the phrase, ‘the more the merrier’. However, that might not hold true with mutual funds. Read on to find out why.

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

DSIJ Intelligence Article rating: 3.5

The market opened in green on August 5, 2020, overall volumes in futures & options currently stand at 2,11,51,827 crore contracts with a turnover of Rs. 14,46,632.04 crore.

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

DSIJ Intelligence Article rating: 3.5

The market opened in green on August 5, 2020, overall volumes in futures & options currently stand at 2,11,51,827 crore contracts with a turnover of Rs. 14,46,632.04 crore.

Alembic Pharma gets USFDA approval for Vardenafil Hydrochloride tablets
Alembic Pharma gets USFDA approval for Vardenafil Hydrochloride tablets

Alembic Pharma gets USFDA approval for Vardenafil Hydrochloride tablets

Apurva Joshi Article rating: 4.0

Alembic Pharmaceuticals Limited has received final approval from United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Vardenafil Hydrochloride tablets, 2.5 mg (base), 5 mg (base), 10 mg (base), and 20 mg (base).

Parag Milk Foods gain 3 per cent on further release of pledged shares
Parag Milk Foods gain 3 per cent on further release of pledged shares

Parag Milk Foods gain 3 per cent on further release of pledged shares

Nidhi Jani Article rating: 4.0

The promoters have released 27 lakh equity shares, with reference to the earlier announcements. The promoters have informed the company that they have repaid Rs 58.09 crore and now the outstanding amount is Rs 5.91 crore.

RSS
First28912892289328942896289828992900Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR